Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Hannes Bucher (Biberach an der Riss, Germany), Hannes Bucher, Birgit Jung, Klaus J. Erb. Efficacy of dexamethasone, roflumilast and azithromycin in a murine cigarette smoke/NTHi infection model. Eur Respir J 2016; 48: Suppl. 60, 2620

Member's Comments

No comment yet.

Related content which might interest you: Assesment of the effects of tocilizumab, adalimumab and steroid in LPS induced acute lung inflammation Source: International Congress 2016 – Airway response to infection Year: 2016 Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE) Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 The combination of TNF-α neutralization and dexamethasone treatment restored the corticosteroid responsiveness in tobacco smoking mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Effects of tobacco smoke and poly IC, alone and in combination, on mouse lung pathology Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Ciclesonide and tiotropium synergistically inhibit airway eosinophilia in a guinea pig model of chronic asthma Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Azithromycin exhibits interferon-inducing properties in an experimental mouse model of asthma exacerbation Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Effect of carbocysteine lysine salt on frequency of exacerbations in COPD patient treated with or without inhaled steroids Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Impact of mucolytic treatment on COPD exacerbations Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013 Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD Source: Annual Congress 2013 –COPD treatment Year: 2013